BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
68.63
-0.29 (-0.42%)
At close: Jun 23, 2026, 4:00 PM EDT
69.00
+0.37 (0.54%)
After-hours: Jun 23, 2026, 7:09 PM EDT

BridgeBio Pharma Stock Forecast

Stock Price Forecast

According to 24 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Strong Buy" and an average price target of $102.28. The average 1-year stock price forecast is 49.03% higher than the current stock price, while the lowest is $76 (+10.74%) and the highest is $157 (+128.76%).

Price Target: $102.28 (+49.03%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$76$102.28$100$157
Change+10.74%+49.03%+45.71%+128.76%

Analyst Ratings

The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy151516161516
Buy555666
Hold111122
Sell000000
Strong Sell000000
Total212122232324

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Raymond James
Raymond James
Buy
Maintains
$125$98
BuyMaintains$125$98+42.79%Jun 17, 2026
Mizuho Securities
Mizuho Securities
Buy
Maintains
$106$96
BuyMaintains$106$96+39.88%Jun 15, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
$101
BuyMaintains$101+47.17%Jun 11, 2026
Barclays
Barclays
Buy
Maintains
$157
BuyMaintains$157+128.76%Jun 5, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Initiates
$104
BuyInitiates$104+51.54%Jun 3, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
968.76M
from 502.08M
Increased by 92.95%
Revenue Next Year
1.60B
from 968.76M
Increased by 65.28%
EPS This Year
-2.18
from -3.78
EPS Next Year
0.53
from -2.18
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
69.72M77.65M9.30M221.90M502.08M968.76M
Revenue Growth
745.15%11.38%-88.02%2,285.27%126.26%92.95%
Gross Profit
66.60M74.21M6.86M218.02M481.11M901.27M
Gross Margin
95.53%95.58%73.71%98.25%95.82%93.03%
Operating Income
-573.33M-468.44M-599.44M-577.37M-502.06M-306.49M
Net Income
-562.54M-481.18M-643.20M-535.76M-724.93M-434.20M
EPS
-----3.78-2.18
Free Cash Flow
-301.13M-285.88M-240.16M-291.12M-325.29M-271.47M
No. Analysts
-----22
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.1B
Avg968.8M
Low844.4M

Revenue Growth

Revenue Growth202620272028
High
120.2%
Avg
93.0%
Low
68.2%

EPS Forecast

EPS202620272028
High-1.49
Avg-2.18
Low-2.62

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-